WASHINGTON, Dec. 22 (TNSFR) -- The Food and Drug Administration (FDA) has revealed a reorganization within its Center for Drug Evaluation and Research (CDER), specifically within the Office of Medical Policy (OMP), aimed at enhancing the agency's capacity to address emerging challenges in clinical trials. Approved by the Secretary of Health and Human Services on November 19, 2024, the restructuring is designed to modernize clinical trial processes and integrate advanced technologies into dr . . .

Click here for more information about our products